CytRx (CYTR) Getting Somewhat Favorable Media Coverage, Study Shows
News coverage about CytRx (NASDAQ:CYTR) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CytRx earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.7888512481837 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences (finance.yahoo.com)
- Comparing CytRx (CYTR) & The Competition (americanbankingnews.com)
- CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates (finance.yahoo.com)
- ValuEngine Downgrades CytRx (CYTR) to Strong Sell (americanbankingnews.com)
Shares of CytRx (NASDAQ CYTR) traded up $0.03 during midday trading on Friday, hitting $1.97. The company had a trading volume of 199,999 shares, compared to its average volume of 280,401. CytRx has a 1-year low of $1.71 and a 1-year high of $6.00.
Separately, ValuEngine cut CytRx from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/cytrx-cytr-getting-somewhat-favorable-media-coverage-study-shows/1756136.html.
CytRx Company Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
Receive News & Ratings for CytRx Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Co. and related companies with MarketBeat.com's FREE daily email newsletter.